
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded suppository containing paromomycin sulfate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing paromomycin are listed in capsule form. No finished paromomycin product of any kind is listed in suppository form.
Suppository bases differ, and the base used decides how USP <795> classifies the preparation for beyond-use dating. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Paromomycin is an oral aminoglycoside antibiotic that compounding pharmacies prepare as capsules, suspensions and topical preparations by prescription.
Paromomycin sulfate is an aminoglycoside antibiotic produced by a Streptomyces species, with antibacterial action that closely parallels neomycin. Like other aminoglycosides it interferes with protein synthesis in susceptible organisms, and it is active against the intestinal parasite Entamoeba histolytica and against Leishmania. Taken by mouth it is poorly absorbed, so almost all of a dose stays in the gut and is recovered in the stool. The manufactured product is Humatin (paromomycin sulfate) capsules, which are FDA-approved for intestinal amebiasis (acute and chronic) and as adjunctive therapy in the management of hepatic coma; the label states it "is not effective in extraintestinal amebiasis." A prescriber may order paromomycin compounded when a patient needs a liquid, a smaller strength for a child, a topical preparation, or a dye-free capsule. Compounded paromomycin preparations are not FDA-approved and require a prescription.
The Humatin label carries no boxed warning. It is contraindicated in people with prior hypersensitivity to paromomycin and in intestinal obstruction. The label advises caution with ulcerative lesions of the bowel, because drug absorbed through damaged bowel could reach the kidneys and cause renal toxicity. Like other antibiotics it can allow overgrowth of non-susceptible organisms, including fungi. The label has no drug interaction, pregnancy or nursing sections. No breastfeeding data have been published; because paromomycin is poorly absorbed orally it is unlikely to reach the infant. Injectable paromomycin studied for leishmaniasis caused hearing loss and kidney effects in a few patients, known aminoglycoside risks. The most reported side effects of the capsules are nausea, abdominal cramps and diarrhea. Finish the full course even if you feel better. If diarrhea is severe, you develop ringing in the ears or reduced hearing, or you notice a change in urination, talk to your prescriber or pharmacist.
Paromomycin is an aminoglycoside structurally related to neomycin; the antileishmanial mechanism is incompletely characterized and is thought to involve inhibition of ribosomal translocation and subunit recycling plus altered mitochondrial membrane potential. After oral dosing it is poorly absorbed, with nearly 100 percent recovered in feces, so systemic aminoglycoside toxicity is not expected unless mucosal integrity is compromised. Labeled indications (Humatin capsules): intestinal amebiasis, acute and chronic, and adjunctive therapy for hepatic coma. The label advises use only for infections "proven or strongly suspected" to be caused by susceptible organisms, to limit resistance. Prescribers have ordered compounded topical paromomycin for Old World cutaneous leishmaniasis, where randomized trials used paromomycin with methylbenzethonium chloride or urea in ointment bases; local reactions (pain, burning, pruritus, erythema, edema) tended to be more frequent with the paromomycin plus methylbenzethonium chloride formulation, without reaching statistical significance, and the authors judged the evidence limited (Kim et al., PLoS NTD 2009). Intramuscular paromomycin, studied for visceral leishmaniasis on the Indian subcontinent (Pokharel et al., Journal of Tropical Medicine 2021), is outside the US label. Dosing is per prescriber. Monitor renal function if bowel ulceration is present, and audiometry if any parenteral exposure occurs. Paromomycin is not a controlled substance.
Wash your hands. If the suppository is soft, chill it in its wrapper in the refrigerator or under cool water for a few minutes, then unwrap it. For rectal use, coat the tip with a water-soluble lubricant (not petroleum jelly), lie on your side with your upper knee bent, and insert it pointed end first past the muscle at the opening. For vaginal use, lie on your back with knees bent and insert it as far as it comfortably goes, by finger or applicator; bedtime use limits leakage, and a panty liner protects clothing. Stay lying down about 15 minutes. Wash your hands.
Suppositories are nonaqueous, so under USP <795> they can carry a beyond-use date of up to 180 days at controlled room temperature or in the refrigerator when no other stability data apply. Storage depends on the base: fatty bases can soften at room temperature and may be labeled for the refrigerator, while polyethylene glycol bases usually do not need refrigeration. Keep them cool so they do not melt, and refrigerate them if your label says to.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Insert 1 unwrapped suppository